Finerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
NephrologyFinerenone vs Placebo in Type 1 Diabetes and CKD: Updates From the Phase 3 FINE-ONE Trial From the Kidney Meeting 2025 in Houston
Implications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
NephrologyImplications of the FINE-ONE Trial: How Might Recently Presented Data From the 2025 Kidney Meeting Influence the Current Treatment Paradigm for Type 1 Diabetes and CKD?
New Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
NephrologyNew Data From the CONFIDENCE Trial: The Effect of Combination Empagliflozin and Finerenone on UACR and eGFR in CKD and Type 2 Diabetes
The Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
NephrologyThe Impact of Finerenone Plus Empagliflozin on Hyperkalemia in the CONFIDENCE Trial
Diuretic Response in the ICU: A Practical Predictor of Renal Trajectory
Clinician's RoundtableDiuretic Response in the ICU: A Practical Predictor of Renal Trajectory
AIP Emerges as a Potential Marker for Diabetic Kidney Risk
Clinician's RoundtableAIP Emerges as a Potential Marker for Diabetic Kidney Risk
- advertisement
- advertisement
The Immunomodulating Role of B Cells in IgA Nephropathy: Focus On APRIL
Medical Industry FeatureThe Immunomodulating Role of B Cells in IgA Nephropathy: Focus On APRIL
The Pathogenesis of Complement 3 Glomerulopathy (C3G)
Medical Industry FeatureThe Pathogenesis of Complement 3 Glomerulopathy (C3G)
The Endothelin System and IgAN: Emerging Evidence
Medical Industry FeatureThe Endothelin System and IgAN: Emerging Evidence
IgAN Insights: The Impact of Proteinuria
Medical Industry FeatureIgAN Insights: The Impact of Proteinuria
- 12/05/2025
- 12/04/2025
- 12/03/2025
- 12/03/2025
- 12/02/2025
- 12/01/2025